title: Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.
abstract: Meningitec is a CRM197-conjugated meningococcal serogroup C (MenC) vaccine, first licensed in 1999. It has been used as a primary and booster vaccine in infants, toddlers, older children and adults, and has been shown to be immunogenic and well-tolerated in all age groups, including premature infants. Vaccine effectiveness has been demonstrated using combined data on all three licensed MenC conjugate vaccines. Evidence from clinical trials, however, suggests that the different MenC conjugate vaccines behave differently with respect to the induction and persistence of bactericidal antibody and generation of immune memory. It appears that Meningitec has a less favorable immunologic profile compared particularly to tetanus toxoid (TT) MenC conjugate vaccines. Data from comparative trials have raised interesting questions on priming of the immune system by conjugate vaccines, particularly in infants. The results from these and other studies are reviewed here with specific focus on Meningitec.
authors.affiliation: a National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS), The Children's Hospital at Westmead, and the Discipline of Paediatrics and Child Health, Sydney Medical School , The University of Sydney , Sydney , NSW , Australia.|b Department of Family and Community Medicine, Faculty of Medicine in Rabigh , King Abdulaziz University , Jeddah , Saudi Arabia.
authors.forename: Al-Mamoon
authors.initials: AM
authors.lastname: Badahdah
authors.affiliation: a National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS), The Children's Hospital at Westmead, and the Discipline of Paediatrics and Child Health, Sydney Medical School , The University of Sydney , Sydney , NSW , Australia.|c Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Biological Sciences and Sydney Medical School , University of Sydney , Sydney , NSW , Australia.
authors.forename: Harunor
authors.initials: H
authors.lastname: Rashid
authors.affiliation: d Department of Paediatrics , Sydney Medical School, The University of Sydney , Sydney , NSW , Australia.
authors.forename: Ameneh
authors.initials: A
authors.lastname: Khatami
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D007114:Immunization / Q000379:methods; D008585:Meningitis, Meningococcal / Q000382:microbiology* / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D038542:Neisseria meningitidis, Serogroup C / Q000276:immunology*; D016896:Treatment Outcome; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: C506687:MCP-CRM197 conjugate vaccine; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate
keywords: Meningitec; Neisseria meningitidis; conjugate vaccine; meningitis; meningococcal serogroup C